Eye infectious disorder

Summary

Eye infectious disorder (MONDO:0043885) is a disease (an umbrella term covering 10 Mondo subtypes) with 1 GWAS associations across 9 studies and 20 clinical trials. Top therapeutic interventions include moxifloxacin, povidone-iodine, and azithromycin. A subtype of eye disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 10 Mondo subtypes
• GWAS associations: 1
• Clinical trials: 20

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	eye infectious disorder
Mondo ID	MONDO:0043885
MeSH	D015817
NCIT	C45372
SNOMED CT	128351009
UMLS	C0015403
MedGen	41934
Anatomy (UBERON)	UBERON:0000970
Is cancer (heuristic)	no

Also known as: eye infection · infection, eye · infection, ocular · infections, eye · infections, ocular · ocular infection · ocular infections

Data availability: 1 GWAS association (9 studies).

Disease family

This is a subtype of eye disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › eye infectious disorder

Related subtypes (119): ptosis, eye accommodation disease, corneal disorder, asthenopia, lens disorder, keratomalacia, scleral disorder, ocular siderosis, coloboma, luxation of globe, mucopolysaccharidosis type 1, lacrimal apparatus disorder, Foster-Kennedy syndrome, anterior dislocation of lens, uveal disorder, eyelid disorder, ocular hypotension, scotoma, exophthalmos, ophthalmia nodosa, eye degenerative disorder, refractive error, glaucoma, retinal disorder, eye allergy, ocular vascular disorder, optic neuritis, conjunctival disorder, ocular hypertension, Tietz syndrome, Alagille syndrome, glaucoma-sleep apnea syndrome, Marshall syndrome, microcornea-glaucoma-absent frontal sinuses syndrome, nail-patella syndrome, oculodentodigital dysplasia, piebaldism, Sturge-Weber syndrome, cerebrotendinous xanthomatosis, ocular cystinosis, alpha-mannosidosis, megalocornea-intellectual disability syndrome, mucolipidosis type IV, mucopolysaccharidosis type 6, Netherton syndrome, galactosialidosis, Niemann-Pick disease type A, ocular motor apraxia, Cogan type, Peters plus syndrome, isolated Pierre-Robin syndrome, ectodermal dysplasia-blindness syndrome, Sandhoff disease, SHORT syndrome, Sjogren-Larsson syndrome, Smith-Lemli-Opitz syndrome, Tay-Sachs disease, tyrosinemia type II, Ito hypomelanosis, X-linked cone dysfunction syndrome with myopia, red color blindness, oculocerebrorenal syndrome, Lowry-MacLean syndrome, pigment dispersion syndrome, hereditary hyperferritinemia with congenital cataracts, dyssegmental dysplasia-glaucoma syndrome, mevalonic aciduria, familial cavitary optic disk anomaly, blindness - scoliosis - arachnodactyly syndrome, fatty acyl-CoA reductase 1 deficiency, microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome, neurotrophic keratopathy, Cogan syndrome, atopic keratoconjunctivitis, rhizomelic chondrodysplasia punctata, Ehlers-Danlos syndrome, kyphoscoliotic type 1, IRVAN syndrome, Rothmund-Thomson syndrome type 2, microcornea-corectopia-macular hypoplasia syndrome, isolated anophthalmia-microphthalmia syndrome, Spasmus nutans, toxic maculopathy due to antimalarial drugs, syndromic recessive X-linked ichthyosis, acute zonal occult outer retinopathy, acute annular outer retinopathy, phakomatosis pigmentovascularis, lamellar ichthyosis, idiopathic linear interstitial keratitis, chondroectodermal dysplasia with night blindness, galactosemia, GM1 gangliosidosis, Gaucher disease, visual snow syndrome, extensive peripapillary myelinated nerve fibers, IgG4-related ophthalmic disorder, global developmental delay-visual anomalies-progressive cerebellar atrophy-truncal hypotonia syndrome, vernal keratoconjunctivitis, Gardner syndrome, anterior segment dysgenesis, isolated ankyloblepharon filiforme adnatum, hereditary optic neuropathy, essential strabismus, Axenfeld anomaly, eye neoplasm, isolated blepharochalasis, punctate inner choroidopathy, vitreous body disorder, 9q33.3q34.11 microdeletion syndrome, autoimmune/inflammatory optic neuropathy, LTBP2-related ocular dysgenesis, ocular growth disorder, ocular dysgenesis caused by defects in PAX6 regulation, choroidal neovascularization, anterior segment developmental abnormality with extraocular manifestations, congenital optic disk excavation, neuroocular syndrome, isolated angioid streaks, multiple evanescent white dot syndrome, stellate multiform amelanotic choroidopathy, macular telangiectasia

Subtypes (10): chronic canaliculitis, hordeolum, bacterial conjunctivitis, ocular tuberculosis, endophthalmitis, infectious panuveitis, fungal infection of eye, parasitic eye infection, viral eye infection, infectious scleritis

Genetics & variants

GWAS landscape

1 GWAS associations across 9 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs148838922	1e-07	TAB3 - FTHL17	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90477713	Verma A	2024	13,874	410,374	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477712	Verma A	2024	5,483	106,185	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481112	Verma A	2024	5,483	106,185	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651844	Liu TY	2025	2,479	217,632	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90477711	Verma A	2024	2,161	53,425	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90079324	Backman JD	2021	1,271	109,604	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083310	Backman JD	2021	1,271	109,604	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90436000	Zhou W	2018	560	399,306	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90481921	Verma A	2024	211	6,245	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	1
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs148838922	X	31052261	A>G	0.05	intron_variant	TAB3 - FTHL17	1e-07	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

49 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Acyclovir	Approved (phase 4)
Amikacin	Approved (phase 4)
Ampicillin	Approved (phase 4)
Azithromycin	Approved (phase 4)
Bacitracin	Approved (phase 4)
Besifloxacin	Approved (phase 4)
Cefmenoxime	Approved (phase 4)
Cefuroxime	Approved (phase 4)
Chloramphenicol	Approved (phase 4)
Chlorhexidine	Approved (phase 4)
Chlortetracycline	Approved (phase 4)
Ciprofloxacin	Approved (phase 4)
Dihydrostreptomycin	Approved (phase 4)
Erythromycin	Approved (phase 4)
Famciclovir	Approved (phase 4)
Fomivirsen	Approved (phase 4)
Fusidic Acid	Approved (phase 4)
Ganciclovir	Approved (phase 4)
Gatifloxacin	Approved (phase 4)
Gentamicin	Approved (phase 4)
Hexamidine	Approved (phase 4)
Idoxuridine	Approved (phase 4)
Interferon	Approved (phase 4)
Kanamycin	Approved (phase 4)
Lomefloxacin	Approved (phase 4)
Moxifloxacin	Approved (phase 4)
Natamycin	Approved (phase 4)
Neomycin	Approved (phase 4)
Netilmicin	Approved (phase 4)
Nitrofurazone	Approved (phase 4)
Norfloxacin	Approved (phase 4)
Ofloxacin	Approved (phase 4)
Oxytetracycline	Approved (phase 4)
Penicillin G	Approved (phase 4)
Polihexanide	Approved (phase 4)
Polymyxin B	Approved (phase 4)
Povidone-Iodine	Approved (phase 4)
Rifamycin	Approved (phase 4)
Sulfacetamide	Approved (phase 4)
Sulfadicramide	Approved (phase 4)
Sulfamethizole	Approved (phase 4)
Sulfaphenazole	Approved (phase 4)
Sulfisoxazole	Approved (phase 4)
Tetracycline	Approved (phase 4)
Tobramycin	Approved (phase 4)
Trifluridine	Approved (phase 4)
Tyrothricin	Approved (phase 4)
Vancomycin	Approved (phase 4)
Vidarabine	Approved (phase 4)
Framycetin	Phase 3 (in late-stage trials)
Prednisolone	Phase 3 (in late-stage trials)
Prednisolone Acetate	Phase 3 (in late-stage trials)
Propamidine	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 20.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	7
Not specified	7
PHASE3	4
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00347828	PHASE4	UNKNOWN	Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose
NCT00564447	PHASE4	COMPLETED	Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers
NCT00575367	PHASE4	COMPLETED	Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers
NCT00575380	PHASE4	COMPLETED	Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery
NCT01739920	PHASE4	COMPLETED	Comparative Efficacy of Different Regimens of PVPI 5% Eye Drops Instillation in Reducing Conjunctival Bacterial Flora
NCT04087733	PHASE4	COMPLETED	Effectiveness of Liposomial Ozonized-Oil for Cataract Surgery
NCT04745663	PHASE4	TERMINATED	Optimizing Preoperative Disinfection of Eyes
NCT00000130	PHASE3	COMPLETED	Endophthalmitis Vitrectomy Study (EVS)
NCT00198523	PHASE3	COMPLETED	A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
NCT00335088	PHASE3	UNKNOWN	Local Moxifloxacin and Povidone Iodine Versus Povidone Iodine Alone as a Prophylaxis Before Eye Operations
NCT01603030	PHASE3	UNKNOWN	Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation
NCT01853722	PHASE2	COMPLETED	A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers
NCT06720467	PHASE2	COMPLETED	Immunotherapy in Eyelid Viral Papilloma
NCT06579170	Not specified	ACTIVE_NOT_RECRUITING	Burden of Recreational Water Illness Due to Exposure to Cyanobacteria and Their Toxins in Freshwater Beaches in Canada
NCT06775808	Not specified	RECRUITING	Total Infectome Characterization of Eye Infections
NCT07418333	Not specified	NOT_YET_RECRUITING	Efficacy of EPD-09-25 for Eyelid Hygiene Before and After Eye Surgery.
NCT01817478	Not specified	UNKNOWN	The Influence of Hospital Environment on Eyes Infections in Medical Staff
NCT03420820	Not specified	UNKNOWN	Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection
NCT03553017	Not specified	COMPLETED	The EXPLORE Study - The Use of Binocular OCT Imaging for the Assessment of Ocular Disease
NCT04075669	Not specified	UNKNOWN	Multiplex Strip Polymerase Chain Reaction for Diagnosis of Eye Infection Diseases From Corneal Scraping Samples

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MOXIFLOXACIN	4	3
POVIDONE-IODINE	4	2
AZITHROMYCIN	4	1
TOBRAMYCIN	4	1
CHEMBL4299381	0	1